Next, we clarify whether epalrestat treatment is achieved by inhibiting NLRP3 inflammasome activation in NASH, so active caspase-1 expression and pro-inflammatory cytokine secretion were tested in liver tissue after epalrestat treatment. The gene discussed is NLRP3; the disease is metabolic dysfunction-associated steatohepatitis.